Copyright 2002 Pfizer Inc Internet2 & Pharma Industry National Priorities for Transforming...

Copyright 2002 Pfizer Inc

Internet2 & Pharma IndustryNational Priorities for Transforming Healthcare Quality Report - implications for patient safety and internet applications

Ernest T. AndalcioExecutive Director, Site Head Informatics

Pfizer Global Research & DevelopmentApril 10, 2003


Intro

Ernest Andalcio - Executive Director - Ann Arbor Labs

With Pfizer for 5 years before that Bristol-Myers Squibb, Johnson & Johnson

and Procter & Gamble Responsible for mobilizing the talents of IT staff

to identify, design, develop and implement robust technology solutions enabling delivery of scientific excellence, and for promoting best practices, fostering IT knowledge-sharing and exploring innovative new technologies


Intro

Challenges for Pharma Industry Opportunities Share some Learnings


Topics/Contents

Pharmaceutical Industry Challenges Opportunities Learnings


Pfizer Research & Development Largest privately funded biomedicalresearch organization

Seven major research sites

2002 R & D investment of $5.3 billion

Count on a few new medicines to reachthe market each year

4 filings planned for 2003

Target of 20 filings in next 5 years

Mission…”We will be the most consistently productive R&D organization in the industry.”


Topics/Contents



Challenges in our Industry

Balancing Patient needs Medicine Patents New Regulations Profitability Risk Social responsibility Shareholder expectations


Clinical Trials Require More Patients

35674237

5779

1321

1981-84 1989-92 1994-95 1998-2000

35674237

5779

1321

1981-84 1989-92 1994-95 1998-2000

Source: Parexel Pharmaceutical R&D Statistical Sourcebook 2001; Centerwatch, An Industry in Evolution 2001

Worldwide Industry Number of Patients per NCEWorldwide Industry Number of Patients per NCE


Challenges - the long road to a new medicine & how Internet2solutions could one-day help the process

Discovery

Exploratory Development

Full Development

Registration


Most

Compounds

Do Not Become

Medicines

Most

Compounds

Do Not Become

Medicines

Challenges - R&D Attrition (why new chemical entities

fail)

Complex Disease Targets

Impractical To Make

Not Sufficiently

Selective

Competition

Unsafe

Poor Absorption

Low Levels in Body Unstable

Adverse Reactions

Not Effective Enough

Side Effects

Too Long in Body


Pharmaceutical Technology in Action

Gather, analyze and present valuable and timely information to therapeutic project teams for high-priority targets.

Use information to help identify novel, high quality targets that may be pursued by the therapeutic project teams.

Data Mining Sequence Analysis Information Storage/Retrieval (Database) Information Presentation


The Challenge…

Biology: The Target

• Select the disease-related protein• Understand its function and role

Biology: The Target

• Select the disease-related protein• Understand its function and role

Chemistry: The Compound

• Optimize the potency• Avoid adverse pharmacokinetics• Avoid adverse toxic effects

Chemistry: The Compound

• Optimize the potency• Avoid adverse pharmacokinetics• Avoid adverse toxic effects


Topics/Contents



Opportunities - The Future of Medicine

Freedom from heart disease

A full, normal life for diabetics

Preserving the antibiotic miracle

Taking the fear out of cancer

Eliminating frailty in the elderly

Preventing Alzheimer’s disease


Opportunities - The Future of Medicine

Cardiovascular Disease

HIV/AIDs

Urogenital

Pulmonary

Central Nervous System

Diabetes

Women’s Health

20 new filings in next 5 years


Opportunities - Pharma Informatics Increase productivity

Seek different ways of working to increase the number of medicines that make it to full development annually

Enable new business processes: Improve data/information for timely decision-making

Leverage Scale Take advantage of Global Capacity Maximize use of Best Practices: Quality and

Architecture of systems used


Topics/Contents



Learnings - Opportunities for Internet2 to make

it happen

Due to the nature of our business - research - enabling technologies like Internet2 aid internal global execution of the R&D process E.g. “Flipping through” large, secure files (e.g. x-ray

images) to spot changes in size of tumors Pfizer does global R&D, however, due to the

nature of our business – highly proprietary – it is a largely secure intranet environment: though we accept information from outside

vendors using “safe zones” technologies


Learnings - Opportunities for Internet2 to make it happen

Enabling new business processes Streamlined Discovery & Development

processes Improved data/information for more timely

(real-time) decision-making (Hi bandwidth human interactions! “Charles Yun”)

First-time Better Earlier

Enabling Digital Science “David G. Messerschmidt”


Summary

Pharma Industry (Challenges/Opportunities) Pharmaceutical R&D processes Internet2… can enable real-time analysis,

dialogue and … “discovery” of new medicines


QUESTIONS?

[email protected]

Copyright 2002 Pfizer Inc Internet2 & Pharma Industry National Priorities for Transforming...

Documents

Transcript of Copyright 2002 Pfizer Inc Internet2 & Pharma Industry National Priorities for Transforming...